Aiming of becoming a leader within the treatment of addiction

Presentation of sales potential for the pharma projects and the digital therapies at the CMD today

MARCH 17, 2020 – On the Capital Markets Day today the company will present the sales potential for both the pharma projects and the digital therapies. Among others OX124 is expected to reach a sales potential of USD 70 m – USD 110 m in the US.

View our CMD video!

On March 17 Orexo hosted a Capital Markets Day focusing on the company’s strategy for growth. At the CMD members of the management team, including recently appointed EVP DTx, Dennis Urbaniak, provided an update on the company´s strategy, pipeline and business opportunities within digital health. Also speaking was Dr. Mario Weiss, CEO and Founder of GAIA AG, a global leader in DTx.

Notice of the AGM

MARCH 23, 2020 - Orexos shareholders are summoned to the Annual General Meeting, Thursday April 16, at 4 pm CET in Orexo’s head quarter in Uppsala, Sweden. To avoid the spread of COVID-19 we please ask you to read our Visitation Policy before attending in person. To read the notice please see below link and for further related information please see About Us/Corporate Governance/AGM at the web where all documents are available.

Proxy Form for the AGM

23 MARS, 2020 – Orexos shareholders are summoned to the Annual General Meeting, Thursday April 16, at 4 pm CET in Orexo’s head quarter in Uppsala, Sweden. If you want a proxy to vote on your behalf please find the proxy form below.

vorvida® submitted with FDA

MARCH 6, 2020 - To enable commercialization of vorvida® in the US an application has been submitted to FDA. vorvida®, is a digital therapy with clinically proven efficacy for the treatment of heavy alcohol use. Subject to hearing from FDA, which is expected in Q2 2020, Orexo intends to initiate the commercialization in H2 2020.

Promising results for OX338

JANUARY 29, 2020 - The PK study for OX338, evaluating novel formulations of ketorolac for the treatment of pain showed promising results. The formulations demonstrated improved bioavailability and tolerability compared to the commercially available reference product. The next step is to further optimise the formulation to ensure obtaining a unique product profile and strong IP protection.